BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07C 275/34, C07D 317/60, C07C 317/50, C07D 405/12, 407/12, 409/12, 417/12, 413/12, C07C 323/60, C07K 5/02, A61K 31/195, 31/36, 31/41

A3

(11) International Publication Number: **WO 99/24398**

(43) International Publication Date: 20 May 1999 (20.05.99)

(21) International Application Number: PCT/GB98/03334

(22) International Filing Date: 9 November 1998 (09.11.98)

(30) Priority Data:
9723789.5 12 November 1997 (12.11.97) GB

(71) Applicant *(for all designated States except US)*: ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: BRITTAIN, David, Robert [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). JOHNSTONE, Craig [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(74) Agent: BRYANT, Tracey; Zeneca Pharmaceuticals, Intellectual Property Dept., Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(88) Date of publication of the international search report:
5 August 1999 (05.08.99)

(54) Title: UREA DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS



(II)



(A)



(B)

(57) Abstract

Compounds of formula (II) where R^1 is in the para or meta position and is (A); R^2 and R^3 are each independently selected from hydrogen, nitro, C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-4}alkoxyl, C_{1-6}alkylamino, C_{1-6}dialkylamino, C_{1-6}alkylC_{1-4}alkoxyl, C_{1-6}alkylaminoC_{1-6}alkyl, amino, cyano, halogeno, trifluoromethyl, $-CO_2R^{12}$ and $-CONR^{12}R^{13}$, where R^{12} and R^{13} are independently selected from hydrogen or C_{1-6}alkyl, or R^2 and R^3 together with the phenyl to which they are attached form a 9 or 10 membered bicyclic ring system; R^4 is C_{1-4}alkyl; R^5 is selected from hydrogen and C_{1-4}alkyl; R^6 is selected from C_{1-6}alkyl, C_{1-4}alkyl(C_{4-6})cycloalkyl, C_{1-6}alkyl(C_{1-6})alkoxyl, C_{1-6}alkylS(C_{1-6})alkyl, C_{1-4}alkylsulphonyl(C_{1-4})alkyl; (B) where q is an integer from 1 to 6 and R^{14} is halogeno; R^7 is selected from C_{1-6}alkyl, C_{1-8}alkoxylcarbonyl, C_{2-6}alkenyl, 1,3–benzodioxol–5–yl and aryl each optionally substituted by one or more substituents selected from C_{1-4}alkoxy, C_{1-6}alkyl, cyano, halogeno, and trifluoromethyl; R^8 is aryl, heteroaryl, a bicyclic heteroaryl ring system linked to the nitrogen via a ring carbon or a 9 or 10 membered bicyclic ring system linked to the nitrogen via a ring carbon and each ring is optionally substituted with up to two substituents, which may be the same or different, and are selected from C_{1-6}alkyl, C_{1-4}alkoxy, C_{1-4}alkylthio, C_{1-6}alkylC_{1-4}alkoxyl, C_{1-6}alkylaminoC_{1-6}alkyl, hydroxy, $-CO_2H$, $-(CH_2)_pOH$ where p is 1 or 2, cyano, halogeno, and trifluoromethyl; R^9 and R^{10} are each independently selected from hydrogen and C_{1-4}alkyl or R^8 and R^9 together with the nitrogen to which they are attached form a dihydroindolyl, or a dihidroquinolinyl group; R^{11} is selected from carboxyl, tetrazolyl, alkyl sulphonylcarbamyl, sulfo and sulfino; Y is oxygen, sulphur or sulfonyl; m is 0 or 1; and n is 0 or an integer from 1 to 4 with the proviso that when m and n cannot both be 0 and when m is 1, n is 0; or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof. The compounds inhibit the interaction of vascular cell–adhesion molecule–1 and fibronectin with integrin very late antigen 4 ($\alpha_4\beta_1$). They have therapeutic applications such as in multiple sclerosis, rheumatoid arthritis, asthma, coronary artery disease and psoriasis.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

INTERNATIONAL SEARCH REPORT

Inter. nal Application No
PCT/GB 98/03334

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07C275/34 C07D317/60 C07C317/50 C07D405/12 C07D407/12
C07D409/12 C07D417/12 C07D413/12 C07C323/60 C07K5/02
A61K31/195 A61K31/36 A61K31/41

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07C C07D A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 22966 A (BIOGEN INC) 1 August 1996 cited in the application see table 1; claims 1, 28-33	1,6,8-10
A	WO 97 08145 A (G.D. SEARLE & CO) 6 March 1997 see page 4, line 18 - page 13, line 6; examples 108, 124	1,6,8-10

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
12 May 1999	21/05/1999

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Van Amsterdam, L

1

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 98/03334

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.: 8-9
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 8-9 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. [ ] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

information on patent family members

Intern ıal Application No
PCT/GB 98/03334

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9622966 A	01-08-1996	AU	4911596 A	14-08-1996
		BG	101841 A	30-04-1998
		BR	9606778 A	06-01-1998
		CA	2211181 A	01-08-1996
		CN	1177343 A	25-03-1998
		CZ	9702340 A	18-03-1998
		EP	0805796 A	12-11-1997
		FI	973087 A	22-09-1997
		HU	9702461 A	28-04-1998
		JP	10513160 T	15-12-1998
		NO	973384 A	19-09-1997
		PL	321848 A	22-12-1997
		SK	98797 A	04-02-1998
WO 9708145 A	06-03-1997	AU	702487 B	25-02-1999
		AU	7103996 A	19-03-1997
		CA	2230209 A	06-03-1997
		CN	1201454 A	09-12-1998
		CZ	9800341 A	16-09-1998
		EP	0850221 A	01-07-1998
		NO	980817 A	24-04-1998
		NZ	318926 A	29-04-1999
		PL	325312 A	20-07-1998